 1. Any prior VEGF-directed therapy including VEGF antibody eg, bevacizumab, VEGF receptor tyrosine kinase inhibitor eg, sunitinib, sorafenib, axitinib, pazopanib, etc., VEGF trap eg, aflibercept, or any other agent or investigational agent targeting the VEGF pathway. 